A1362
Agomelatine
≥98% (HPLC)
Sinonimo/i:
N-[2-(7-Methoxy-1-naphthalenyl)ethyl]-acetamide, S-20098
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Scegli un formato
5 MG
CHF 87.40
25 MG
CHF 350.00
Scegli un formato
Cambia visualizzazione
5 MG
CHF 87.40
25 MG
CHF 350.00
About This Item
Formula empirica (notazione di Hill):
C15H17NO2
Numero CAS:
Peso molecolare:
243.30
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77
Prodotti consigliati
Saggio
≥98% (HPLC)
Stato
powder
Colore
white to off-white
Solubilità
DMSO: >50 mg/mL
Ideatore
Servier
Temperatura di conservazione
2-8°C
Stringa SMILE
COc1ccc2cccc(CCNC(C)=O)c2c1
InChI
1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
YJYPHIXNFHFHND-UHFFFAOYSA-N
Informazioni sul gene
human ... HTR2C(3358) , MTNR1A(4543) , MTNR1B(4544)
Applicazioni
Agomelatine has been used:
- to study its effects on adult neurogenesis and hippocampus apoptosis using the stress-induced depression model of rats[1]
- to explore its effects on tau protein phosphorylation and to study its neuroprotective mechanism[2]
- to study its effects on intracellular calcium ([Ca2+]i) signaling in peripheral neurons of rat dorsal root ganglion (DRG) neurons[3]
Azioni biochim/fisiol
Agomelatine is an extremely potent agonist at both melatonin receptors (MT1 and MT2), with additional antagonism at 5HT2C.
Agomelatine is an extremely potent agonist at both melatonin receptors (MT1 and MT2), with additional antagonism at 5HT2C. It is a novel antidepressant with many desired in vivo properties, including neuroprotection and neurogenesis in depression-sensitive brain areas. Agomelatine′s efficacy appears to be due to both melatonergic and serotonergic properties. In neurogenesis assays, both in vitro and in vivo, the compound effects were differentially affected by antagonists for MT1/MT2 and 5HT2C, demonstrating actions through all three receptors.
Agomelatine modulates the sleep-wake cycle through its chronobiotic activity. It normalizes the sleep pattern in patients suffering from depression and seasonal mood disorder.[1]
Caratteristiche e vantaggi
This compound is featured on the Melatonin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Avvertenze
Warning
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Aquatic Acute 1 - Aquatic Chronic 1
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
Non trovi la versione di tuo interesse?
Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
Trevor R Norman
Expert opinion on investigational drugs, 22(4), 407-410 (2013-03-15)
Alteration of nocturnal melatonin production, along with circadian rhythm disturbance, has been demonstrated in several psychiatric disorders. It has been postulated that such disturbances might be causal reflecting a more fundamental abnormality of the function of the suprachiasmatic nucleus (SCN).
Nikos Maniadakis et al.
BMC health services research, 13, 173-173 (2013-05-15)
Major depressive disorder (MDD) constitutes an important public health problem, as it is highly prevalent in the industrialized world and it is associated with substantial economic consequences for patients, health care providers, insurance and social security organizations and employers. To
Siegfried Kasper et al.
International clinical psychopharmacology, 28(1), 12-19 (2012-10-02)
Pooled analysis of individual patient data was used to compare the antidepressant efficacy of agomelatine with that of selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs). We sought head-to-head, double-blind, randomized studies without a placebo arm
Alejandro Martínez-Águila et al.
European journal of pharmacology, 701(1-3), 213-217 (2012-12-29)
In the search for new compounds to reduce intraocular pressure (IOP), with fewer side effects, we have found that agomelatine, a melatonin analogue, can reduce IOP being, therefore, interesting for the treatment of ocular hypertension and glaucoma. In normotensive conditions
Michelle Nigri Levitan et al.
Experimental and clinical psychopharmacology, 20(6), 504-509 (2012-10-24)
Agomelatine is an antidepressant with a novel mechanism of being a selective melatonergic MT₁/MT₂ receptor agonist with serotonin 5-HT(2c) receptor antagonist activities. Although the vast majority of the clinical data concerning the effectiveness of agomelatine concern its antidepressant properties, there
Active Filters
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.
